{"name": "omidenepag isopropyl", "category": "drug", "content": "Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.   == Medical uses == Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.   == Adverse effects == The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.   == Pharmacology == Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.   == History == Omidenepag was developed by Ube Industries and Santen Pharmaceutical.   == References ==   == External links == \"Omidenepag\". Drug Information Portal. U.S. National Library of Medicine. \"Omidenepag isopropyl\". Drug Information Portal. U.S. National Library of Medicine. \"Omidenepag\". NCI Thesaurus. \"Omidenepag isopropyl\". NCI Thesaurus."}